Biosyent Inc. (CVE:RX) insider Kevin Wilson acquired 22,576 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The stock was acquired at an average price of C$7.21 per share, with a total value of C$162,772.96.
ILLEGAL ACTIVITY WARNING: “Biosyent Inc. (RX) Insider Kevin Wilson Purchases 22,576 Shares” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/04/20/insider-buying-biosyent-inc-rx-insider-acquires-22576-shares-of-stock-updated-updated.html.
Separately, Bloom Burton restated an “accumulate” rating on shares of Biosyent in a report on Monday, February 13th.
Biosyent Company Profile
BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.